Progyny price target raised to $35 from $30 at BTIG

1 day ago 1

TipRanks

Thu, January 22, 2026 astatine 6:20 AM CST 1 min read

BTIG raised the firm’s price target connected Progyny (PGNY) to $35 from $30 and keeps a Buy standing connected the shares pursuing the JP Morgan Healthcare Conference. The institution sees Q4 revenue, nett income, and adjusted EBITDA to beryllium somewhat supra erstwhile guidance owed to subordinate engagement tracking favorably comparative to expectations, the expert tells investors successful a probe note. Demand, caller lawsuit wins, and subordinate adds are each good, and Progyny continues to physique connected its industry-leading presumption wrong fertility and household building, the steadfast added.

Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions
Stay up of the marketplace with the latest quality and investigation and maximize your portfolio's potential

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See the apical stocks recommended by analysts >>

Read More connected PGNY:

Disclaimer & DisclosureReport an Issue

Progyny upgraded to Outperform from Market Perform astatine Citizens
Progyny expects Q4 gross ‘slightly above’ ranges provided successful November
Progyny upgraded to Buy from Hold astatine Truist
Progyny terms people raised to $32 from $30 astatine KeyBanc
Progyny President’s Employment to End December 2025

Read Entire Article